Deep Dive: Page 7
Industry insights from our journalists
-
Elizabeth Regan/BioPharma Dive
Pharma gets serious about AI: BioPharma Dive's 2018 predictions
The technology is playing its part to change the way pharma interacts with patients.
Lisa LaMotta • Jan. 5, 2018 -
Drug approvals surged in 2017. What does that mean for pharma?
The FDA approved more novel medicines in 2017 than in any year since 1996.
Ned Pagliarulo • Jan. 3, 2018 -
Elizabeth Regan/BioPharma Dive
Regulatory reforms unstick CMO market in China
A pilot scheme introduced by the Chinese government has given domestic biopharma companies more flexibility to tap CMOs for their manufacturing needs.
Wang Fangqing • Dec. 21, 2017 -
Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths, National Institutes of Health. (2015). "Killer T cells surround a cancer cell" [Image]. Retrieved from Flickr.
Chasing leaders, Juno rides CAR-T momentum into ASH
This year's ASH conference will be an important milestone in Juno's comeback bid, showcasing early progress of its lead CAR-T therapy in lymphoma.
Ned Pagliarulo • Dec. 7, 2017 -
Spark CEO Marrazzo hints at million dollar price tag
As potential approval of the first gene therapy for a rare form of blindness approaches, the problem of pricing still lacks an easy solution.
Lisa LaMotta • Dec. 4, 2017 -
Yujin Kim/BioPharma Dive
The BioPharma Dive Awards for 2017
The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.
Ned Pagliarulo, Lisa LaMotta and Jacob Bell • Dec. 4, 2017 -
Most Damaging Clinical Trial Failure: AstraZeneca's MYSTIC
Imfinzi's miss in non-small cell lung cancer was a huge setback for the British pharma and could relegate the drug as a never-was in the checkpoint inhibitor race.
Lisa LaMotta • Dec. 4, 2017 -
Most Impressive Drug Launch: Roche's Ocrevus
The first drug to win approval for primary progressive multiple sclerosis, Ocrevus' strong launch has already put the drug on a blockbuster trajectory.
Ned Pagliarulo • Dec. 4, 2017 -
Deal of the Year: Gilead Buys Kite Pharma
Faced with a waning hepatitis C business, Gilead finally came off the M&A sidelines to buy itself a leading position in CAR-T cell therapy.
Ned Pagliarulo • Dec. 4, 2017 -
Elizabeth Regan/BioPharma Dive
Disruption of the Year: Long-Acting Hemophilia Drugs
Longer-acting treatments and gene therapies are likely to steal away hundreds of millions of dollars worth of revenue from established products in the coming years.
Jacob Bell • Dec. 4, 2017 -
Biotech of the Year: Vertex Pharmaceuticals
Vertex watched its stock more than double in 2017 as the company cornered the multi-billion-dollar cystic fibrosis market with strong products and a promising pipeline.
Jacob Bell • Dec. 4, 2017 -
Executive of the Year: Kenneth Frazier
Merck's CEO has navigated the company through some of its most difficult years and brought it back to its science-focused roots, while also standing out as a pillar of morality.
Lisa LaMotta • Dec. 4, 2017 -
Pharma of the Year: AbbVie
Humira has been the best-selling drug in the world several years running, showing no signs of slowing down. But AbbVie is taking no chances, building up a strong pipeline.
Lisa LaMotta • Dec. 4, 2017 -
How Anthem's new PBM will impact pharma
David Henka, CEO of RxTE Health, sat down with BioPharma Dive to discuss the implications of a new pharmacy benefit manager entering the marketplace.
Jacob Bell • Nov. 28, 2017 -
Barriers remain for a drug industry ready to blossom in Brazil
A poor patient population, a tricky tax code and turmoil within the government have created obstacles for pharma companies entering the Brazilian market.
Jacob Bell • Oct. 30, 2017 -
Elizabeth Regan/BioPharma Dive
Pharma's betting big on China, but R&D boom still to come
Despite a major regulatory shift, China's ascendency as the next global hub of drug R&D may still be a ways off.
Ned Pagliarulo • Oct. 30, 2017 -
Time for PTC to shift gears?
With a negative review from an FDA advisory committee and low prospects for approval, the time may have arrived for PTC Therapeutics to reevaluate its business plan.
Lisa LaMotta • Sept. 29, 2017 -
A drug 15 years in the making: Alnylam's quest to prove RNAi
This month's success from the APOLLO study puts the biotech on the brink of making the technology a medical reality for patients.
Ned Pagliarulo • Sept. 29, 2017 -
5 Trends shaping the pharma sales force
Many factors have played a role in shrinking the pharma sales force. But sales reps aren't going away — their role is just changing.
Lisa LaMotta • Sept. 18, 2017 -
Digital pharma sales technologies soar
Digital contact with physicians has changed the role of the sales rep and made it easier to track patient data.
Malorye Allison Branca • Sept. 18, 2017 -
Elizabeth Regan/BioPharma Dive
How to optimize pharma sales forces in a changing marketplace
Less time with doctors, an increase in rare disease drugs and higher use of digital tools means it's important to find the right talent and use reps efficiently.
Jacob Bell • Sept. 18, 2017 -
Smaller sales forces get the job done in rare disease
The shift from primary care to specialty medicines has meant rightsizing sales forces to match markets.
Ned Pagliarulo • Sept. 18, 2017 -
5 Trends influencing drug pricing
When pricing medications, drugmakers now weigh consumer outrage, negotiating power and calls for transparency.
Jacob Bell • Aug. 14, 2017 -
As federal efforts slow, states take up drug pricing pushback
A bruising healthcare fight has sapped Congressional momentum to tackle rising pharmaceutical prices. But efforts at the state-level could pose a challenge to a drug industry still struggling to find its footing in post-Shkreli world.
Ned Pagliarulo • Aug. 14, 2017 -
Unfazed by competition, Allergan sees room at CGRP table
Allergan believes it can break into the emerging CGRP migraine market, even as it lags behind other drugmakers' rival products.
Ned Pagliarulo • July 28, 2017
Previous
